AstraZeneca PLC (NASDAQ:AZN) Shares Purchased by Bay Colony Advisory Group Inc d b a Bay Colony Advisors

by · The Markets Daily

Bay Colony Advisory Group Inc d b a Bay Colony Advisors boosted its holdings in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 3.4% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 21,581 shares of the company’s stock after purchasing an additional 700 shares during the period. Bay Colony Advisory Group Inc d b a Bay Colony Advisors’ holdings in AstraZeneca were worth $1,681,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Stratos Wealth Advisors LLC boosted its holdings in shares of AstraZeneca by 2.0% in the third quarter. Stratos Wealth Advisors LLC now owns 6,699 shares of the company’s stock valued at $522,000 after acquiring an additional 133 shares in the last quarter. Bruce G. Allen Investments LLC boosted its holdings in shares of AstraZeneca by 19.1% in the second quarter. Bruce G. Allen Investments LLC now owns 860 shares of the company’s stock valued at $67,000 after acquiring an additional 138 shares in the last quarter. Carnegie Investment Counsel boosted its holdings in shares of AstraZeneca by 0.8% in the second quarter. Carnegie Investment Counsel now owns 17,269 shares of the company’s stock valued at $1,347,000 after acquiring an additional 138 shares in the last quarter. CANADA LIFE ASSURANCE Co boosted its holdings in shares of AstraZeneca by 40.6% in the first quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the company’s stock valued at $34,000 after acquiring an additional 146 shares in the last quarter. Finally, Sunpointe LLC boosted its holdings in shares of AstraZeneca by 4.5% in the second quarter. Sunpointe LLC now owns 3,419 shares of the company’s stock valued at $267,000 after acquiring an additional 147 shares in the last quarter. 20.35% of the stock is owned by hedge funds and other institutional investors.

AstraZeneca Price Performance

AZN traded down $0.03 during midday trading on Monday, reaching $75.02. 476,176 shares of the company’s stock were exchanged, compared to its average volume of 4,986,422. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.89 and a quick ratio of 0.69. The stock has a market capitalization of $232.61 billion, a PE ratio of 36.26, a P/E/G ratio of 1.39 and a beta of 0.46. The business’s 50-day moving average price is $80.40 and its 200 day moving average price is $78.59. AstraZeneca PLC has a 1-year low of $60.47 and a 1-year high of $87.68.

AstraZeneca (NASDAQ:AZN – Get Free Report) last posted its quarterly earnings data on Thursday, July 25th. The company reported $0.99 earnings per share for the quarter, beating analysts’ consensus estimates of $0.98 by $0.01. The business had revenue of $12.45 billion during the quarter, compared to analyst estimates of $12.62 billion. AstraZeneca had a net margin of 13.11% and a return on equity of 29.34%. The company’s revenue was up 9.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.08 earnings per share. As a group, equities analysts anticipate that AstraZeneca PLC will post 4.07 EPS for the current fiscal year.

Wall Street Analyst Weigh In

AZN has been the topic of several analyst reports. Deutsche Bank Aktiengesellschaft downgraded shares of AstraZeneca from a “hold” rating to a “sell” rating in a report on Friday, September 13th. Erste Group Bank raised shares of AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. Finally, TD Cowen boosted their price objective on shares of AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a report on Monday, August 12th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $89.75.

Check Out Our Latest Research Report on AstraZeneca

About AstraZeneca

(Free Report)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.

Featured Stories